Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - glimepiride (unii: 6ky687524k) (glimepiride - unii:6ky687524k) - glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. (see dosage and administration section ).   glimepiride tablets are contraindicated in patients with 1. known hypersensitivity to the drug. 2. diabetic ketoacidosis, with or without coma. this condition should be treated with insulin. 

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

remedyrepack inc. - doxycycline hyclate (unii: 19xts3t51u) (doxycycline anhydrous - unii:334895s862) - to reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate capsules and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. doxycycline is indicated for the treatment of the following infections: - rocky mountain spotted fever, typhus fever and the typhus group, q fever, rickettsialpox, and tick fevers caused by rickettsiae. - respiratory tract infections caused by mycoplasma pneumoniae . - lymphogranuloma venereum caused by chlamydia trachomatis . - psittacosis (ornithosis) caused by chlamydophil a   psittaci . - trachoma caused by chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. - inclusion conjunctivitis caused by chlamydia trachomatis . - uncomplicated urethral, endocervical, or rectal infections in adults caused by chlamydia trachomatis. - nongonococcal urethritis caused by ureaplasma urealyticum . - relapsing fever due to borrelia recurrentis . doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: - chancroid caused by haemophilus ducrey i . - plague due to y ersinia pestis . - tularemia due to francisella tularensis . - cholera caused by vibrio cholerae. - campylobacter fetus infections caused by campylobacter fetus . - brucellosis due to brucella species (in conjunction with streptomycin). - bartonellosis due to bartonella bacilliformis . - granuloma inguinale caused by klebsiella granulomatis . because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. doxycycline is indicated for treatment of infections caused by the following gram-negative bacteria, when bacteriologic testing indicates appropriate susceptibility to the drug: - escherichia coli. - enterobacter aerogenes . - shigella species. - acinetobacter species. - respiratory tract infections caused by haemophil us influenzae . - respiratory tract and urinary tract infections caused by klebsiella species. doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: - upper respiratory infections caused by streptococcus pneumoniae . - anthrax due to bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized bacillus anthracis . when penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: - uncomplicated gonorrhea caused by neisseria gonorrhoeae . - syphilis caused by treponema pallidum . - yaws caused by treponema pallidum subspecies   pertenue . - listeriosis due to listeria mo n ocytogenes . - vincent’s infection caused by fusobacterium fusiforme . - actinomycosis caused by actinomyces israe l i i . - infections caused by clostridium species. in acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. in severe acne, doxycycline may be useful adjunctive therapy. doxycycline is indicated for the prophylaxis of malaria due to plasmodium falciparum in short-term travelers (<4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant strains (see dosage and administration section and information for patients subsection of the precautions section). this drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

a-s medication solutions - methylprednisolone acetate (unii: 43502p7f0p) (methylprednisolone - unii:x4w7zr7023) - when oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of depo-medrol sterile aqueous suspension is indicated as follows: allergic states : control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. dermatologic diseases : bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (stevens-johnson syndrome). endocrine disorders : primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. gastrointestinal diseases : to tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. hematologic disorders : acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (diamond blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. miscellaneous : trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. neoplastic diseases : for palliative management of: leukemias and lymphomas. nervous system : cerebral edema associated with primary or metastatic brain tumor or craniotomy. ophthalmic diseases : sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. renal diseases : to induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. respiratory diseases : berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. rheumatic disorders : as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). for the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. (see warnings) depo-medrol is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. depo-medrol is indicated for intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis) and psoriatic plaques; necrobiosis lipoidica diabeticorum. depo-medrol also may be useful in cystic tumors of an aponeurosis or tendon (ganglia). depo-medrol is contraindicated in patients with known hypersensitivity to the product and its constituents. intramuscular corticosteroid preparations are contraindicated for idiopathic thrombocytopenic purpura. depo-medrol is contraindicated for intrathecal administration. this formulation of methylprednisolone acetate has been associated with reports of severe medical events when administered by this route. depo-medrol is contraindicated in systemic fungal infections, except when administered as an intra-articular injection for localized joint conditions (see warnings: infections, fungal infections ).

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

pharmacia & upjohn company llc - methylprednisolone acetate (unii: 43502p7f0p) (methylprednisolone - unii:x4w7zr7023) - when oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of depo-medrol sterile aqueous suspension is indicated as follows: allergic states : control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. dermatologic diseases : bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (stevens-johnson syndrome). endocrine disorders : primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. gastrointestinal diseases : to tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. hematologic disorders : acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (diamond blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. miscellaneous : trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. neoplastic diseases : for palliative management of: leukemias and lymphomas. nervous system : cerebral edema associated with primary or metastatic brain tumor or craniotomy. ophthalmic diseases : sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. renal diseases : to induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. respiratory diseases : berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. rheumatic disorders : as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). for the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. (see warnings) depo-medrol is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. depo-medrol is indicated for intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis) and psoriatic plaques; necrobiosis lipoidica diabeticorum. depo-medrol also may be useful in cystic tumors of an aponeurosis or tendon (ganglia). depo-medrol is contraindicated in patients with known hypersensitivity to the product and its constituents. intramuscular corticosteroid preparations are contraindicated for idiopathic thrombocytopenic purpura. depo-medrol is contraindicated for intrathecal administration. this formulation of methylprednisolone acetate has been associated with reports of severe medical events when administered by this route. depo-medrol is contraindicated in systemic fungal infections, except when administered as an intra-articular injection for localized joint conditions (see warnings: infections, fungal infections ).

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium tablets, usp and other antibacterial drugs, amoxicillin and clavulanate potassium tablets, usp should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. amoxicillin and clavulanate potassium tablets, usp is a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated in the treatment of infections due to susceptible isolates of the designated bacteria in the conditions listed below*: caused by beta-lactamase-producing isolates of haemophilus influenzae and moraxella catarrhalis . caused by beta-lactamase-producing isolates of h. influenza  and m. c

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - doxycycline hyclate (unii: 19xts3t51u) (doxycycline anhydrous - unii:334895s862) - to reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate capsules and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. doxycycline is indicated for the treatment of the following infections: - rocky mountain spotted fever, typhus fever and the typhus group, q fever, rickettsialpox, and tick fevers caused by rickettsiae. - respiratory tract infections caused by mycoplasma pneumoniae . - lymphogranuloma venereum caused by chlamydia trachomatis . - psittacosis (ornithosis) caused by chlamydophil a   psittaci . - trachoma caused by chlamydia trachomatis ,

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - methylphenidate hydrochloride - prolonged-release tablet - 18 milligram(s) - centrally acting sympathomimetics; methylphenidate

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

bryant ranch prepack - oxycodone hydrochloride (unii: c1enj2te6c) (oxycodone - unii:cd35pmg570) - oxycodone hydrochloride tablets is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.1)], reserve oxycodone hydrochloride tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or opioid combination products): • have not been tolerated or are not expected to be tolerated, • have not provided adequate analgesia or are not expected to provide adequate analgesia. oxycodone hydrochloride tablets is contraindicated in patients with: • significant respiratory depression [see warnings and precautions (5.3)]. • acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment or hypercarbia [see warnings and precautions (5.7)]. • known or suspected gastrointestinal obstruction, in

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

bryant ranch prepack - bumetanide (unii: 0y2s3xuq5h) (bumetanide - unii:0y2s3xuq5h) - bumetanide tablets usp are indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome. almost equal diuretic response occurs after oral and parenteral administration of bumetanide. therefore, if impaired gastrointestinal absorption is suspected or oral administration is not practical, bumetanide should be given by the intramuscular or intravenous route. successful treatment with bumetanide tablets usp following instances of allergic reactions to furosemide suggests a lack of cross-sensitivity. bumetanide is contraindicated in anuria. although bumetanide tablets can be used to induce diuresis in renal insufficiency, any marked increase in blood urea nitrogen or creatinine, or the development of oliguria during therapy of patients with progressive renal disease, is an indication for discontinuation of treatment with bumetanide tablets. bumetanide is also contraindicated in patients in hepatic coma or in states of severe electrolyte

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

bryant ranch prepack - minoxidil (unii: 5965120sh1) (minoxidil - unii:5965120sh1) - because of the potential for serious adverse effects, minoxidil tablets are indicated only in the treatment of hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs. at the present time use in milder degrees of hypertension is not recommended because the benefit-risk relationship in such patients has not been defined. minoxidil reduced supine diastolic blood pressure by 20 mmhg or to 90 mmhg or less in approximately 75% of patients, most of who had hypertension that could not be controlled by other drugs. minoxidil tablets are contraindicated in pheochromocytoma, because it may stimulate secretion of catecholamines from the tumor through its antihypertensive action. minoxidil is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.